Cervomed Q2 FY26 net loss widens 5% to $6.57 million; revenue turns to none

Reuters2026/08/07 20:28

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cervomed posted a net loss of $6.57 million in Q2, widening 5% from the prior-year quarter.
Operating loss was $6.68 million, up 1%, as no grant revenue was recognized versus $1.76 million a year earlier.
Total operating expenses fell 20% to $6.68 million, with R&D down 15% to $4.32 million and G&A down 28% to $2.36 million.
Cash, cash equivalents, and marketable securities totaled about $24.9 million at June 30, 2026; liquidity runway projected through Q3 2027.
June financings raised about $20.5 million gross; strategic priority set to secure a partner to advance neflamapimod into Phase 3 in DLB.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-026592), on August 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cervomed Q2 FY26 net loss widens 5% to $6.57 million; revenue turns to none

You may also like

Crypto prices